Form 4: Supernus Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Supernus Pharmaceuticals Director Charles W. Newhall III sold 25,000 shares of common stock on October 9, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Charles W. Newhall III, a Director of Supernus Pharmaceuticals, Inc. (SUPN), reported the sale of common stock.
- The transactions occurred on October 9, 2025.
- A total of 25,000 shares of common stock were disposed of in two separate transactions.
- The first transaction involved 23,800 shares sold at a weighted average price of $50.73 per share, with prices ranging from $50.12 to $51.08.
- The second transaction involved 1,200 shares sold at a weighted average price of $51.55 per share, with prices ranging from $51.39 to $51.76.
- These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2025.
- Following these transactions, Charles W. Newhall III beneficially owns 104,644 shares of Supernus Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The director's sale of shares was executed under a pre-arranged 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to specific company news, leading to a neutral sentiment.
Negatives
- A director's sale of shares, even if pre-planned, can sometimes be perceived negatively by the market as it reduces insider ownership.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing reports an individual insider transaction and does not provide direct insights into broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | Director Charles W. Newhall III executed stock sales under a Rule 10b5-1 trading plan, which was adopted on March 3, 2025. | March 3, 2025 | The use of a 10b5-1 plan provides an affirmative defense against insider trading allegations by pre-scheduling transactions, enhancing transparency and reducing potential market speculation regarding the timing of insider sales. |
Stakeholder Impact
- Shareholders may interpret the director's sale as a signal, though the pre-planned nature via a 10b5-1 plan mitigates immediate concerns about new negative information.
Key Dates
| Date | Description |
|---|---|
| March 3, 2025 | Date the Rule 10b5-1 trading plan was adopted. |
| October 9, 2025 | Date of the reported stock transactions. |
| October 10, 2025 | Date the Form 4 was signed. |
Recommendation
holdThe director's sale of 25,000 shares, while a reduction in insider ownership, was conducted under a pre-established 10b5-1 trading plan adopted several months prior. This suggests a planned liquidity event rather than a reaction to new, undisclosed negative information. As such, this single transaction does not fundamentally alter the investment thesis for Supernus Pharmaceuticals, but it warrants continued monitoring of insider activity and company performance.
Keywords
Supernus Pharmaceuticals, SUPN, Form 4, Insider Trading, Stock Sale, Director, Charles W. Newhall III, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.